New mechanistic findings are pointing to actionable vulnerabilities across solid tumors. A study linked the chromatin partner role of p300 and CBP to YAP-driven transcription in GNAQ-mutant uveal melanoma, identifying p300 as an essential node via CRISPR synthetic-lethal screening. The work adds a new therapeutic target for a tumor subtype with limited durable options. In pancreatic cancer, researchers identified RRM2 as a bridge between nucleotide metabolism and SREBP1/FASN-driven lipid remodeling that supports gemcitabine resistance, aligning metabolic reprogramming with failure of standard chemotherapy. Another report described how NEAT1-built paraspeckles shape pancreatic cancer identity and ferroptosis resistance, pointing to a subtype-specific metabolic weakness. Across the broader space of therapeutic modalities, a computational and preclinical push toward next-generation targeted degradation continues. A separate computational study discussed CRBN modulator candidates as a route around IMiD resistance in PROTAC settings, while a review summarized how PROTACs recruit the ubiquitin-proteasome system to degrade breast cancer proteins. Collectively, the cluster shows a tight loop between genome-scale screens, metabolic phenotyping, and tractable intervention points—suggesting that combination strategies may increasingly be guided by chromatin and lipid/ferroptosis dependencies rather than single-driver genetics alone.